Benzinga | Nov 5, 2020 09:21AM EST

Sanara MedTech Announces Launch Of BIAKOS Antimicrobial Wound Gel; Says 'Results using the liquid form of BIAKOS showed a 98.4% reduction in viral load on a porcine skin explant after 30 seconds'

FORT WORTH, TX / ACCESSWIRE / November 5, 2020 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara" or the "Company") (NASDAQ:SMTI), a provider of wound and skin care products dedicated to improving patient outcomes, announced the launch of BIAKOS(tm) Antimicrobial Wound Gel as well as recent viral testing results for BIAKOS(tm) Skin and Wound Cleanser.

BIAKOS(tm) Antimicrobial Wound Gel

BIAKOS(tm) Antimicrobial Wound Gel is an antimicrobial hydrogel wound dressing available from Sanara MedTech Inc. It can be used alone or in combination with BIAKOS(tm) Antimicrobial Skin and Wound Cleanser. Based on laboratory studies, when used in conjunction the products can work together to enhance effectiveness. The cleanser is applied initially to clean a wound and disrupts biofilm microbes (removing 99% in 10 minutes). The gel can then be applied and will remain in the wound for up to 72 hours helping to continue to disrupt biofilm microbes.

When used in clinical settings, BIAKOS(tm) Antimicrobial Wound Gel is indicated for the management of partial and full-thickness wounds, such as diabetic foot ulcers, post-surgical wounds, pressure ulcers, first and second-degree burns, grafts and donor sites.

Safety studies demonstrated that BIAKOS(tm) is biocompatible and supports the wound healing process.

BIAKOS(tm) Antimicrobial Skin and Wound Cleanser Testing Results Against SARS-CoV-2

Rochal Industries recently collaborated with the World Reference Center for Emerging Viruses and Arboviruses, at the University of Texas Medical Branch, Galveston, TX to further test BIAKOS(tm) Antimicrobial Skin and Wound Cleanser's impact on Severe Acute Respiratory Syndrome Coronavirus 2 ("SARS-CoV-2"), the virus that causes Coronavirus Disease 2019 ("COVID-19"). Laboratory studies were performed to determine if BIAKOS(tm) Antimicrobial Skin and Wound Cleanser could reduce viral loads on contact as well as after drying and remaining on the skin as a coating.

Laboratory testing demonstrated that BIAKOS(tm) Antimicrobial Skin and Wound Cleanser reduced SARS-CoV-2 viral loads during the application of the liquid cleanser and as a coating for up to four hours after application. Results using the liquid form of BIAKOS(tm) showed a 98.4% reduction in viral load on a porcine skin explant after 30 seconds, and a 99.3% reduction after 10 minutes. During laboratory evaluation of the product as a coating on the skin (porcine skin explant), the virus was applied four hours after the application of the BIAKOS(tm) Antimicrobial Skin and Wound Cleanser. An 86.5% reduction in viral load was observed 10 minutes after application of the virus and a 99.3% reduction in viral load was observed one hour after application of the virus.

With the properties exhibited in these tests, BIAKOS(tm) Antimicrobial Skin and Wound Cleanser could potentially offer protection for individuals against the SARS-CoV-2 virus while helping to decrease the incidence of skin conditions arising from alcohol-based hand hygiene protocols.

Ron Nixon, Sanara's executive chairman, stated, "Today's announcement highlights Sanara's commitment to bringing innovative products to market. We look forward to getting BIAKOS(tm) gel into the hands of providers and patients as well as continuing to develop our BIAKOS(tm) OTC cleanser."